ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

The Prognostic Value of Plasma Epstein-Barr Viral DNA and Tumor Response to Neoadjuvant Chemotherapy in Advanced-Stage Nasopharyngeal Carcinoma

Liu, Li Ting; Tang, Lin Quan; Chen, Qiu Yan; Zhang, Lu; Guo, Shan Shan; Guo, Ling; Mo, Hao Yuan; Zhao, Chong; Guo, Xiang; Cao, Ka Jia; Qian, Chao Nan; Zeng, Mu Sheng; Bei, Jin Xin; Hong, Ming Huang; Shao, Jian Yong; Sun, Ying; Ma, Jun; Mai, Hai Qiang*中山大学
International Journal of Radiation Oncology Biology Physics2015-11-15DOI: 10.1016/j.ijrobp.2015.08.003
93被引82阅读
引用收藏
分享

摘要

Purpose: To explore the prognostic value of the plasma load of Epstein-Barr viral (EBV) DNA and the tumor response to neoadjuvant chemotherapy (NACT) in advanced-stage nasopharyngeal carcinoma (NPC). Patients and Methods: In all, 185 consecutive patients with stage III to IVb NPC treated with NACT followed by concurrent chemoradiation therapy (CCRT) were prospectively enrolled. The primary endpoint was progression-free survival (PFS), and the secondary endpoints included locoregional relapseefree survival (LRFS) and distant metastasisefree survival (DMFS). Results: EBV DNA was detected in 165 (89%) patients before treatment but was undetectable in 127 (69%) patients after NACT. Detectable EBV DNA levels after NACT were correlated with poor prognosis (3-year PFS 71.8% vs 85.2%, P = .008 and 3-year DMFS 82.5% vs 92.3%, P = .013). An unsatisfactory tumor response (stable disease or disease progression) after NACT was also correlated with poor clinical outcome (3-year PFS 71.1% vs 85.9%, P = .005 and 3-year LRFS 82.7% vs 93.5%, P = .012). Multivariate analysis showed that the EBV DNA level after NACT (hazard ratio [HR] 2.31, 95% CI 1.18-4.54, P = .015) and the tumor response to NACT (HR 2.84, 95% CI 1.42-5.67, P = .003) were both significant prognostic factors for PFS. Multivariate analysis also showed that EBV DNA after NACT was the only significant predictor of DMFS (HR 2.99, 95% CI 1.25-7.15, P = .014) and that tumor response to NACT was the only significant predictor of LRFS (HR 3.31, 95% CI 1.21-9.07, P = .020). Conclusion: Detectable EBV DNA levels and an unsatisfactory tumor response (stable disease or disease progression) after NACT serve as predictors of poor prognosis for patients with advanced-stage NPC. These findings will facilitate further risk stratification, early treatment modification, or both before CCRT.

学科与关键词

关键词
INTENSITY-MODULATED RADIOTHERAPYRANDOMIZED PHASE-IILONG-TERM SURVIVALINDUCTION CHEMOTHERAPYVIRUS DNACONCURRENT CHEMORADIOTHERAPYCISPLATINIMMUNOTHERAPYFLUOROURACILEXPERIENCE
相关
加载中…
  • Plasma Epstein-Barr Virus DNA Load After Induction Chemotherapy Predicts Outcome in Locoregionally Advanced Nasopharyngeal Carcinoma
    Cheng-Long Huang; Zheng-Qiang Sun; Rui Guo; Xu Liu; Yan-Ping Mao; Hao Peng; Li Tian; Ai-Hua Lin; Li Li; Jian-Yong Shao; Ying Sun; Jun Ma; Ling-Long TangInternational Journal of Radiation Oncology Biology Physics, 2019, 104(2): 355-361.
  • Circulating Epstein-Barr virus DNA level post induction chemotherapy contributes to prognostication in advanced-stage nasopharyngeal carcinoma
    Chen, Fo-Ping; Luo, Ying-Shan; Chen, Kai; Li, Jun-Yun; Huo, Lan-Qing; Shi, Liu; Ou-Yang, Yi; Cao, Xin-Ping*European Journal of Cancer, 2021, 151: 63-71.
  • Integrating pre- and post-treatment Plasma Epstein-Barr Virus DNA levels for better prognostic prediction of Nasopharyngeal Carcinoma
    Li, Wanxia; Yang, Chao; Lv, Zehong; Li, Junzheng; Li, Zonghua; Yuan, Xiaofei; Wu, Shuting; Yuan, Yue; Cui, Linchong; Lu, Juan*; Chen, Jing*; Zhao, Feipeng*American Journal of Cancer Research, 2021, 12(9): 2715-2722.被引 11
查看全部 →

发表信息

论文状态
公开发表
期刊
International Journal of Radiation Oncology Biology Physics
发表日期
2015-11-15
卷期
第 93 卷, 第 4 期
页码
862-869
DOI
10.1016/j.ijrobp.2015.08.003
语言
ENGLISH
期刊收录
SCIE
期刊等级
Q1
成果收录
SCIENCEDIRECT · SCIE
资助标注
National Science Foundation for Distinguished Young Scholars of ChinaNational Natural Science Foundation of ChinaNational Science Fund for Distinguished Young Scholars [81425018]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81072226]; 863 Project [2014A020212103]; National Key Basic Research Program of ChinaNational Basic Research Program of China [2013CB910304, 81201629]; Sci-Tech Project Foundation of Guangdong Province [2014A020212103]; Sci-Tech Project Foundation of Guangzhou City [2011J4300100, 2011B031800161]; Sun Yat-sen University Clinical Research 5010 Program; Fundamental Research Funds for the Central UniversitiesFundamental Research Funds for the Central Universities

作者

  • L

    Liu, Li Ting (第一作者)

    sun yat sen univ

  • T

    Tang, Lin Quan

    sun yat sen univ

查看全部 18 位作者收起作者
  • C

    Chen, Qiu Yan

    sun yat sen univ

  • Z

    Zhang, Lu

    sun yat sen univ

  • G

    Guo, Shan Shan

    sun yat sen univ

  • G

    Guo, Ling

    sun yat sen univ

  • M

    Mo, Hao Yuan

    sun yat sen univ

  • Z

    Zhao, Chong

    sun yat sen univ

  • G

    Guo, Xiang

    sun yat sen univ

  • C

    Cao, Ka Jia

    sun yat sen univ

  • Q

    Qian, Chao Nan

    sun yat sen univ

  • Z

    Zeng, Mu Sheng

    sun yat sen univ

  • B

    Bei, Jin Xin

    sun yat sen univ

  • H

    Hong, Ming Huang

    sun yat sen univ

  • S

    Shao, Jian Yong

    sun yat sen univ

  • S

    Sun, Ying

    sun yat sen univ

  • M

    Ma, Jun

    sun yat sen univ

  • M

    Mai, Hai Qiang (通讯)

    sun yat sen univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417